Giustina, Andrea
Biermasz, Nienke
Casanueva, Felipe F.
Fleseriu, Maria
Mortini, Pietro
Strasburger, Christian
van der Lely, A. J.
Wass, John
Melmed, Shlomo http://orcid.org/0000-0002-2355-3447
Banfi, Giuseppe
Barkan, Ariel
Beckers, Albert
Bidlingmaier, Martin
Boguszewski, Cesar http://orcid.org/0000-0002-2355-3447
Brue, Thierry
Buchfelder, Michael
Chanson, Philippe
Chiloiro, Sabrina
Colao, Annamaria
Coopmans, Eva
Esposito, Daniela
Ferone, Diego
Frara, Stefano
Gadelha, Mônica
Geer, Eliza B.
Ghigo, Ezio
Greenman, Yona
Gurnell, Mark
Ho, Ken
Ioachimescu, Adriana
Johannsson, Gudmundur
Jørgensen, Jens Otto
Kaiser, Ursula B.
Karavitaki, Niki
Katznelson, Laurence
Lamberts, Stephen
Losa, Marco
Luger, Anton
Luque, Raúl
Maffei, Pietro
Marazuela, Mónica
Neggers, Sebastian
Pereira, Alberto
Persani, Luca
Petersenn, Stephan
Reincke, Martin
Salvatori, Roberto
Samson, Susan N.
Schilbach, Katharina
Shimon, Ilan
Tsagarakis, Stylianos
Zatelli, Maria Chiara
,
Funding for this research was provided by:
Cedars-Sinai Medical Center
Article History
Accepted: 17 October 2023
First Online: 3 November 2023
Change Date: 6 December 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11102-023-01373-w
Declarations
:
: AB, MB, AG, and RS are Editors of <i>Pituitary</i>. NB, CB, TB, FC, PC, MF, SF, MG, MG, YG, KH, AI, GJ, JOJ, LK, NK, RL, PM, SN, SP, CS, IS, SLS, and AJvdL are Editorial Board Members of <i>Pituitary</i>. SM is Editor-in-Chief of <i>Pituitary</i>. MB has received research support, consultancy, and/or lecture fees from Camurus, Chiasma, Crinetics Pharmaceuticals, Diasorin, IDS, Ionis, IPSEN, Midatech, Novartis, Ono, OPKO, Pfizer, Recordati, Roche, and StrongBridge. CB has received support for investigator-initiated clinical trials from Crinetics and served as speaker or consultant for Ipsen, Recordati, and NovoNordisk. TB has received support for research grants from Pfizer, consultant/speaker agreements with Ipsen and Pfizer, and clinical trials for Crinetics and Debiopharm. PC has received unrestricted research and educational grants from Ipsen, Novartis, and Pfizer, Recordati, and Advanz; has served as an investigator for clinical trials funded by Crinetics, Chiasma, and Debiopharm; is a member of Advisory Boards for Ipsen, Pfizer, Crinetics, Recordati, and Amolyt; and is a speaker for Ipsen, Recordati, and Pfizer. SC has served as an investigator for clinical trials funded by Novartis, Pfizer, Ipsen, and Crinetics; received grants to the institution from Pfizer, Ipsen, and Recordati; and served as an Advisory Board member for Recordati. DE has received lecture fees from Ipsen and Pfizer AB. MF has received grants to the institution from Amryt, Crinetics, Ionis, and Recordati, and occasional consulting fees from Amryt, Camurus, Crinetics, Ipsen, and Recordati. MF has served as an Advisory Board member for Recordati, Crinetics and Ipsen, received speaker fees from Recordati and Ipsen, and served as principal investigator for studies funded by Recordati and Crinetics. SF has received consultancy and speaker fees from Ipsen, Pfizer, Novartis, and Recordati. BG has received research grants to the institution from Amryt/Chiesi and Ionis, and served as an occasional consultant to Amryt/Chiesi and Crinetics. AG has served as a consultant for Ipsen, Pfizer and Recordati and received research grants to the institution from Pfizer and Recordati. MG has served as a member of a speakers bureau for Ipsen Ltd UK and Pfizer. AI has served as principal investigator for institution-directed research grants from Recordati, Xeris and Amryt/Chiesi, and as an occasional consultant for Recordati, Xeris, Amryt/Chiesi, Camurus, and Crinetics. GJ has served as consultant for NovoNordisk and AstraZeneca and received lecture fees from NovoNordisk and Pfizer. JOJ has received lecture fees and unrestricted research grants from Pfizer and Novo Nordisk. PM has received speaker and/or consultancy fees from Pfizer. UBK has served as consultant for ModeX Therapeutics. LK has served as advisor for Camarus, Novo Nordisk, and Strongbridge, and received research funding from Camurus. NK has served as speaker for Pfizer, Ipsen, and Recordati Rare Diseases; as an investigator for Pfizer and Ipsen; and as a Scientific Advisory Board member for Pfizer, Ipsen, and Recordati Rare Diseases. AL has received honoraria for presentations from Pfizer and Ipsen. MM has served on advisory boards and as a speaker for Ipsen, Recordati, and Pfizer. PM has served as principal investigator, and has received consultation fees and research grants from Pfizer, Recordati, and Camurus. SM has received grants to the institution from Recordati and served as an adviser to Recordati, Crinetics, and Ionis. SN has received research grants Pfizer and consultancy grants from Recordati, NovoNordisk, and Crinetics. LP has received congress fees from Merck and Sandoz. SP has served as a speaker at workshops and Advisory Boards for Ipsen, Pfizer, and Recordati. MR has received consulting fees from Crinetics and Ipsen. CS has received speaker fees from Pfizer, and served as an advisor to Debiopharm, NovoNordisk, Chiasma, and Crinetics. IS has served as an investigator for Crinetics, Chiasma, and Debiopharm, and as speaker and consultant for Pfizer, Medison, and NovoNordisk. RS has served as a consultant for NovoNordisk, Amryt, and Camurus. SLS has served as principal investigator and conducted research studies supported by Novartis and Chiasma. ST has received grants to the institution from Crinetics, honoraria for lectures/presentations from Recordati, and support for attending meetings and/or travel from Pfizer, Ipsen, and Recordati, and has served as an Advisory Board member for Pfizer and Recordati. AJvdL has received speaker and/or consultancy fees from Pfizer, Ipsen, Crinetics, Tiburio, and Amolyt Pharma SA. All other authors declare no competing interests.
: Not applicable.